Literature DB >> 1895445

Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines.

D Goldstein1, M O'Leary, J Mitchen, E C Borden, G Wilding.   

Abstract

The effect of interferon beta ser (IFN beta ser) on the growth of three prostatic cancer cell lines DU-145, PC-3 and LNCaP was studied. IFN beta ser inhibited growth of anchorage dependent semiconfluent monolayers and anchorage dependent colony formation of both DU-145 and PC-3 in a dose dependent manner but had no effect on LNCaP. Transforming growth factor beta (TGF beta 1) inhibited proliferation of DU-145 and PC-3 cells in 1% but not 8% fetal calf serum. The combination of TGF beta 1 and IFN beta ser was additive in its effects on growth. Neither epidermal growth factor (EGF) nor transforming growth factor alpha (TGF alpha) reduced the antiproliferative effect of IFN beta ser on these cells. These antiproliferative effects were reproduced in studies on primary epithelial cell cultures derived from prostate specimens with various pathologies. The potential use of IFN beta ser in combination with hormonal therapy to delay the development of hormone refractory tumors is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895445     DOI: 10.1016/s0022-5347(17)38034-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression.

Authors:  Jianyong Shou; Robert Soriano; Simon W Hayward; Gerald R Cunha; P Mickey Williams; Wei-Qiang Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

2.  Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.

Authors:  A Dicitore; E S Grassi; M O Borghi; G Gelmini; M C Cantone; G Gaudenzi; L Persani; M Caraglia; G Vitale
Journal:  J Endocrinol Invest       Date:  2017-03-01       Impact factor: 4.256

Review 3.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells.

Authors:  Xin Li; Baotong Zhang; Qiao Wu; Xinpei Ci; Ranran Zhao; Zhiqian Zhang; Siyuan Xia; Dan Su; Jie Chen; Gui Ma; Liya Fu; Jin-Tang Dong
Journal:  Int J Cancer       Date:  2014-06-28       Impact factor: 7.396

5.  Interferon-beta inhibits liver metastases from murine colon 26 carcinoma and its highly metastatic variant.

Authors:  Shigechika Kohashi; Yuji Sato; Tsuyoshi Fukushima; Hiroki Shomura; Takahiro Oshima; Sun Bairun; Masao Kondo; Yoshie Une; Jun Nishihira; Satoru Todo
Journal:  Surg Today       Date:  2007-05-28       Impact factor: 2.549

6.  Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Authors:  Mihae Song; Robert S DiPaola; Bernadette M Cracchiolo; Darlene G Gibbon; Mira Hellmann; Wilberto Nieves-Neira; Ami Vaidya; Allison R Wagreich; Weichung J Shih; Lorna Rodriguez-Rodriguez
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

7.  Stromal inhibition of prostatic epithelial cell proliferation not mediated by transforming growth factor beta.

Authors:  A Kooistra; A J van den Eijnden-van Raaij; I A Klaij; J C Romijn; F H Schröder
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

8.  Induction of transforming growth factor beta in hormonally treated human prostate cancer.

Authors:  G H Muir; A Butta; R J Shearer; C Fisher; D P Dearnaley; K C Flanders; M B Sporn; A A Colletta
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.